A First-in-Human (FIH) Phase 1/2 Study to Assess Safety, Tolerability, and Preliminary Anti-Tumor Activity of REGN7945, an anti-CD38 x anti-CD28 Costimulatory Bispecific Monoclonal Antibody, in Combination with Linvoseltamab, an anti-BCMA x anti-CD3 Bispecific Monoclonal Antibody, in Participants with Relapsed/Refractory Multiple Myeloma

Project: Research

Project Details

StatusActive
Effective start/end date24/03/25 → 23/03/27

Keywords

  • Clinical Trials
  • R7945-ONC-22110

Clinical Trial Phase

  • Phase I
  • External Sponsor